Head-To-Head Review: Organogenesis (ORGO) versus Its Competitors

Organogenesis (NASDAQ:ORGO) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Organogenesis to related companies based on the strength of its dividends, analyst recommendations, valuation, risk, profitability, earnings and institutional ownership.

Institutional and Insider Ownership

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Organogenesis and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1	2	0	0	1.67
Organogenesis Competitors	9801	15090	45424	1579	2.54

Organogenesis presently has a consensus target price of $4.33, suggesting a potential upside of 432.87%. As a group, “Biotechnology” companies have a potential upside of 100.43%. Given Organogenesis’ higher probable upside, equities research analysts plainly believe Organogenesis is more favorable than its competitors.

Volatility & Risk

Organogenesis has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Organogenesis’ competitors have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Earnings and Valuation

This table compares Organogenesis and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Organogenesis	$564.17 million	$37.03 million	-0.95
Organogenesis Competitors	$735.95 million	$13.62 million	-15.01

Organogenesis’ competitors have higher revenue, but lower earnings than Organogenesis. Organogenesis is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Organogenesis and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organogenesis	-19.94%	-23.89%	-11.13%
Organogenesis Competitors	-12,359.35%	-203.09%	-30.93%

Summary

Organogenesis beats its competitors on 9 of the 13 factors compared.

About Organogenesis

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.